During the last session, Nurix Therapeutics Inc (NASDAQ:NRIX)’s traded shares were 1.06 million, with the beta value of the company hitting 2.27. At the end of the trading day, the stock’s price was $9.80, reflecting an intraday loss of -0.20% or -$0.02. The 52-week high for the NRIX share is $29.56, that puts it down -201.63 from that peak though still a striking 16.53% gain since the share price plummeted to a 52-week low of $8.18. The company’s market capitalization is $747.11M, and the average intraday trading volume over the past 10 days was 1.27 million shares, and the average trade volume was 898.62K shares over the past three months.
Nurix Therapeutics Inc (NRIX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. NRIX has a Sell rating from 0 analyst(s) out of 16 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 13 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.77.
Nurix Therapeutics Inc (NASDAQ:NRIX) trade information
Nurix Therapeutics Inc (NRIX) registered a -0.20% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.20% in intraday trading to $9.80, hitting a weekly high. The stock’s 5-day price performance is 2.08%, and it has moved by -28.26% in 30 days. Based on these gigs, the overall price performance for the year is -36.61%. The short interest in Nurix Therapeutics Inc (NASDAQ:NRIX) is 12.16 million shares and it means that shorts have 12.79 day(s) to cover.
The consensus price target of analysts on Wall Street is $30, which implies an increase of 67.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16 and $35 respectively. As a result, NRIX is trading at a discount of -257.14% off the target high and -63.27% off the low.
Nurix Therapeutics Inc (NRIX) estimates and forecasts
In the rating firms’ projections, revenue will increase 15.21% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 16.26M as predicted by 16 analyst(s). Meanwhile, a consensus of 16 analyst(s) estimates revenue growth to 14.41M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 12.09M and 12.59M respectively. In this case, analysts expect current quarter sales to grow by 34.47% and then jump by 14.45% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -38.86%. While earnings are projected to return -5.57% in 2025, the next five years will return -2.57% per annum.
NRIX Dividends
Nurix Therapeutics Inc is due to release its next quarterly earnings on 2025-Apr-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nurix Therapeutics Inc (NASDAQ:NRIX)’s Major holders
Nurix Therapeutics Inc insiders own 1.40% of total outstanding shares while institutional holders control 109.92%, with the float percentage being 111.48%. BLACKROCK INC. is the largest shareholder of the company, while 252.0 institutions own stock in it. As of 2024-06-30, the company held over 6.82 million shares (or 10.9334% of all shares), a total value of $142.33 million in shares.
The next largest institutional holding, with 4.42 million shares, is of REDMILE GROUP, LLC’s that is approximately 7.0917% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $92.32 million.
Also, the Mutual Funds coming in first place with the largest holdings of Nurix Therapeutics Inc (NRIX) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 2.29 shares. This amounts to just over 3.00 percent of the company’s overall shares, with a $22.41 million market value. The same data shows that the other fund manager holds slightly less at 1.97, or about 2.59% of the stock, which is worth about $19.32 million.
